生物科技公司Akero Therapeutics(AKRO)今日盘中飙升5.83%,股价一度触及56.70美元。
消息面上,美银美林将该公司的股票评级上调至买入,目标价由35美元大幅上调至63美元,参与评级的12家机构中有92%给予该股买入评级,升级幅度之大引发市场强烈反应。
分析师看好Akero Therapeutics潜力股,推动了公司股价今日大涨。该公司是一家临床阶段生物科技公司,正着力开发治疗非酒精性脂肪肝炎药物AKR-001,这一未满足的大疾病市场潜力巨大,预计公司长期将获得不错的增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.